Marc H Levin, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · UCSF Medical Group Business Services · University of California San Francisco
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Levin’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$37,528
Medicare paid this office $37,528 for 211 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 68 | $6,949 | $86 |
| New patient visit (45+ min) | 53 | $6,043 | $114 |
| Return visit (30+ min) | 24 | $1,939 | $69 |
| Short return visit (20+ min) | 31 | $1,761 | $57 |
| New patient visit (30+ min) | 23 | $1,543 | $67 |
See all 11 services
| Return visit (30+ min) | 68 | $6,949 | $86 |
| New patient visit (45+ min) | 53 | $6,043 | $114 |
| Return visit (30+ min) | 24 | $1,939 | $69 |
| Short return visit (20+ min) | 31 | $1,761 | $57 |
| New patient visit (30+ min) | 23 | $1,543 | $67 |
| Exam of visual field with extended testing | 48 | $1,263 | $24 |
| Exam to measure eye deviation and range of motion | 38 | $1,235 | $33 |
| New patient visit (45+ min) | 15 | $979 | $65 |
| Imaging of optic nerve | 40 | $846 | $19 |
| Exam of visual field with extended testing | 16 | $321 | $16 |
| Imaging of optic nerve | 17 | $206 | $12 |
Who their Medicare patients are
211 Original Medicare patients in 2024. Average age 73 · Under 65 7% · 85 and older 5% · Women 55% · Also on Medicaid 11% · Health risk score 1.25. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 64% · Chronic kidney disease 23% · Coronary heart disease 22% · Diabetes 21% · Stroke 21% · Depression 19% · Cancer 18% · Atrial fibrillation 17% · Heart failure 9% · COPD 9% · Dementia 6%.
The office billed $288,190, Medicare allowed $50,140 and paid $37,528; for 491 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 211 | 491 | 73 | 1.25 | $288,190 | $37,528 |
| 2023 | 338 | 1,307 | 75 | 1.12 | $351,481 | $70,184 |
| 2022 | 625 | 1,704 | 75 | 1.04 | $604,359 | $155,736 |
| 2021 | 541 | 2,545 | 75 | 1.08 | $551,471 | $152,743 |
| 2020 | 420 | 1,376 | 74 | 1.30 | $362,237 | $96,538 |
| 2019 | 536 | 1,844 | 73 | 1.16 | $486,760 | $127,972 |
| 2018 | 531 | 2,232 | 73 | 1.21 | $488,884 | $130,202 |
| 2017 | 336 | 1,128 | 73 | 1.29 | $290,893 | $79,268 |
| 2016 | 281 | 501 | 73 | 1.37 | $196,600 | $44,383 |
| 2015 | 132 | 291 | 70 | 1.83 | $119,059 | $14,603 |
| 2014 | 97 | 252 | 70 | 1.19 | $118,629 | $18,995 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 190 | $20,467 | $98 |
| New patient visit (45+ min) | 60 | $7,249 | $121 |
| New patient visit (60+ min) | 34 | $6,119 | $180 |
| Exam to measure eye deviation and range of motion | 98 | $5,451 | $55 |
| Exam of visual field with extended testing | 70 | $3,833 | $50 |
| Long return visit (40+ min) | 18 | $2,847 | $142 |
| Imaging of optic nerve | 77 | $2,608 | $29 |
| Placement of adjustable sutures during eye muscle surgery | 11 | $1,931 | $176 |
| Return visit (30+ min) | 12 | $1,155 | $89 |
| Imaging of optic nerve | 13 | $261 | $20 |
2022: 10 services
| Return visit (30+ min) | 343 | $47,995 | $110 |
| New patient visit (45+ min) | 168 | $23,728 | $141 |
| New patient visit (60+ min) | 88 | $17,180 | $195 |
| Exam to measure eye deviation and range of motion | 269 | $16,097 | $60 |
| Long return visit (40+ min) | 75 | $12,494 | $164 |
| Exam of visual field with extended testing | 121 | $8,527 | $60 |
| Realignment of horizontal eye muscle | 13 | $7,388 | $568 |
| Imaging of optic nerve | 114 | $4,303 | $33 |
| Placement of adjustable sutures during eye muscle surgery | 18 | $3,176 | $176 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $446 | $22 |
2021: 11 services
| Return visit (30+ min) | 304 | $42,009 | $111 |
| New patient visit (45+ min) | 152 | $22,546 | $148 |
| New patient visit (60+ min) | 88 | $17,086 | $194 |
| Exam to measure eye deviation and range of motion | 227 | $14,045 | $62 |
| Realignment of horizontal eye muscle | 14 | $11,394 | $760 |
| Long return visit (40+ min) | 53 | $8,997 | $164 |
| Exam of visual field with extended testing | 127 | $8,552 | $62 |
| Imaging of optic nerve | 96 | $3,661 | $34 |
| Placement of adjustable sutures during eye muscle surgery | 14 | $2,076 | $138 |
| Imaging of retina | 15 | $581 | $39 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $264 | $18 |
2020: 9 services
| Return visit (30+ min) | 247 | $26,859 | $89 |
| New patient visit (60+ min) | 76 | $13,770 | $181 |
| Exam to measure eye deviation and range of motion | 175 | $10,559 | $60 |
| New patient visit (45+ min) | 72 | $9,665 | $134 |
| Long return visit (40+ min) | 56 | $7,375 | $129 |
| Exam of visual field with extended testing | 66 | $4,605 | $61 |
| Imaging of optic nerve | 61 | $2,265 | $33 |
| Placement of adjustable sutures during eye muscle surgery | 12 | $1,662 | $138 |
| Short return visit (20+ min) | 15 | $1,137 | $71 |
2019: 10 services
| Return visit (30+ min) | 312 | $36,865 | $93 |
| New patient visit (45+ min) | 144 | $19,136 | $133 |
| New patient visit (60+ min) | 71 | $13,024 | $183 |
| Exam to measure eye deviation and range of motion | 183 | $11,363 | $62 |
| Realignment of horizontal eye muscle | 15 | $10,122 | $675 |
| Exam of visual field with extended testing | 95 | $6,481 | $64 |
| Long return visit (40+ min) | 33 | $4,441 | $135 |
| Imaging of optic nerve | 94 | $3,597 | $35 |
| Short return visit (20+ min) | 28 | $2,148 | $63 |
| Placement of adjustable sutures during eye muscle surgery | 13 | $1,816 | $140 |
2018: 11 services
| Return visit (30+ min) | 309 | $36,019 | $92 |
| New patient visit (45+ min) | 125 | $18,637 | $149 |
| New patient visit (60+ min) | 83 | $14,461 | $174 |
| Exam to measure eye deviation and range of motion | 173 | $10,684 | $61 |
| Exam of visual field with extended testing | 119 | $8,149 | $59 |
| Realignment of horizontal eye muscle | 12 | $7,923 | $660 |
| Long return visit (40+ min) | 50 | $6,698 | $126 |
| Imaging of optic nerve | 106 | $4,084 | $35 |
| Short return visit (20+ min) | 53 | $3,950 | $64 |
| Placement of adjustable sutures during eye muscle surgery | 13 | $1,790 | $138 |
| Imaging of retina | 17 | $627 | $37 |
2017: 8 services
| Return visit (30+ min) | 159 | $17,313 | $92 |
| New patient visit (60+ min) | 78 | $13,572 | $174 |
| Long return visit (40+ min) | 63 | $8,098 | $125 |
| New patient visit (45+ min) | 49 | $7,038 | $144 |
| Exam to measure eye deviation and range of motion | 102 | $6,144 | $60 |
| Exam of visual field with extended testing | 64 | $4,534 | $61 |
| Short return visit (20+ min) | 35 | $2,325 | $63 |
| Imaging of optic nerve | 53 | $2,106 | $34 |
2016: 12 services
| Return visit (30+ min) | 73 | $8,144 | $99 |
| Long return visit (40+ min) | 36 | $4,514 | $125 |
| New patient visit (45+ min) | 28 | $4,234 | $151 |
| New patient visit (60+ min) | 18 | $3,120 | $173 |
| Short return visit (20+ min) | 40 | $2,883 | $69 |
| Exam of visual field with extended testing | 32 | $2,326 | $65 |
| Exam to measure eye deviation and range of motion | 33 | $2,022 | $61 |
| New patient complete exam of visual system | 23 | $1,760 | $77 |
| Imaging of optic nerve | 38 | $1,700 | $41 |
| Established patient complete exam of visual system | 23 | $1,501 | $60 |
| Established patient problem focused exam of visual system | 24 | $1,007 | $36 |
| Exam of visual field with extended testing | 19 | $525 | $24 |
2015: 6 services
| New patient complete exam of visual system | 53 | $4,680 | $88 |
| Established patient problem focused exam of visual system | 58 | $3,398 | $43 |
| Established patient complete exam of visual system | 26 | $1,838 | $71 |
| Exam of visual field with extended testing | 47 | $1,324 | $23 |
| Imaging of optic nerve | 20 | $468 | $22 |
| Exam to measure eye deviation and range of motion | 12 | $426 | $35 |
2014: 6 services
| New patient complete exam of visual system | 28 | $2,598 | $93 |
| Exam of visual field with extended testing | 41 | $1,474 | $26 |
| Return visit (30+ min) | 13 | $1,194 | $70 |
| Short return visit (20+ min) | 18 | $1,006 | $46 |
| Established patient complete exam of visual system | 11 | $822 | $75 |
| Established patient problem focused exam of visual system | 12 | $645 | $50 |
Medicaid work
$820 in 2018
Medicaid paid $820 for 13 billed services this clinician did in 2018, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 13 | $820 |
| 2018 | 13 | 1 | 13 | $820 |
Drugs they prescribed that Part D paid
$17,614
Pharmacies billed $17,614 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
88 generic and 21 brand-name prescriptions · $17,614 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pyridostigmine | 13 | $1,035 | $80 |
| Neomycin-Polymyxin-Dexameth | 26 | $770 | $30 |
| Latanoprost | 14 | $89 | $6 |
| Prednisone | 11 | $88 | $8 |
Year by year
| 2024 | 109 | 49 | None | 19% | $17,614 |
| 2023 | 203 | 69 | 0% (0) | 33% | $18,596 |
| 2022 | 204 | 96 | 0% (0) | 22% | $23,960 |
| 2021 | 215 | 81 | None | 30% | $20,426 |
| 2020 | 243 | 82 | None | 26% | $23,484 |
| 2019 | 235 | 85 | None | 35% | $22,581 |
| 2018 | 170 | 68 | None | 41% | $19,248 |
| 2017 | 122 | 59 | None | 34% | $10,358 |
| 2016 | 75 | 36 | None | 15% | $3,803 |
| 2015 | 57 | 17 | None | None | $2,109 |
| 2014 | 25 | 14 | None | None | $926 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Pyridostigmine | 21 | $1,925 | $92 |
| Latanoprost | 60 | $847 | $14 |
| Neomycin-Polymyxin-Dexameth | 19 | $572 | $30 |
| Acetazolamide | 16 | $284 | $18 |
| Prednisone | 16 | $223 | $14 |
2022: 6 drugs
| Pyridostigmine | 29 | $4,071 | $140 |
| Fluorometholone | 13 | $1,619 | $125 |
| Latanoprost | 31 | $633 | $20 |
| Neomycin-Polymyxin-Dexameth | 23 | $489 | $21 |
| Prednisone | 27 | $396 | $15 |
| Timolol Maleate | 12 | $252 | $21 |
2021: 7 drugs
| Pyridostigmine | 30 | $3,379 | $113 |
| Fluorometholone | 11 | $1,412 | $128 |
| Latanoprost | 39 | $797 | $20 |
| Neomycin-Polymyxin-Dexameth | 27 | $759 | $28 |
| Prednisone | 17 | $368 | $22 |
| Timolol Maleate | 13 | $181 | $14 |
| Pantoprazole | 11 | $144 | $13 |
2020: 7 drugs
| Pyridostigmine | 24 | $2,626 | $109 |
| Latanoprost | 55 | $995 | $18 |
| Brimonidine | 16 | $665 | $42 |
| Neomycin-Polymyxin-Dexameth | 14 | $407 | $29 |
| Prednisone | 33 | $392 | $12 |
| Timolol Maleate | 18 | $280 | $16 |
| Pantoprazole | 12 | $184 | $15 |
2019: 7 drugs
| Travatan Z | 16 | $3,433 | $215 |
| Brimonidine | 23 | $1,982 | $86 |
| Latanoprost | 69 | $1,358 | $20 |
| Fluorometholone | 11 | $579 | $53 |
| Neomycin-Polymyxin-Dexameth | 11 | $322 | $29 |
| Timolol Maleate | 14 | $232 | $17 |
| Erythromycin | 14 | $173 | $12 |
2018: 4 drugs
| Tobramycin-Dexamethasone | 24 | $3,132 | $130 |
| Pyridostigmine | 12 | $1,030 | $86 |
| Latanoprost | 52 | $919 | $18 |
| Prednisone | 19 | $264 | $14 |
2017: 3 drugs
| Tobramycin-Dexamethasone | 19 | $2,454 | $129 |
| Latanoprost | 27 | $383 | $14 |
| Erythromycin | 11 | $114 | $10 |
2016: 1 drug
| Prednisone | 14 | $306 | $22 |
2015: 2 drugs
| Pyridostigmine | 18 | $927 | $52 |
| Prednisone | 13 | $111 | $9 |
2014: 1 drug
| Neomycin-Polymyxin-Dexameth | 12 | $446 | $37 |
Money from drug and device companies
$8,612 in 2025
| 2025 | 2 | 14 | $8,200 | $8,612 |
| 2024 | 1 | 4 | $21,600 | $21,600 |
| 2023 | 2 | 5 | $23,200 | $23,304 |
| 2020 | 1 | 1 | None | $76 |
| 2019 | 1 | 1 | None | $49 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | None | $8,200 | 11 payments
|
| Abbvie | Botox | $412 | 3 payments
|
See all 14 published payments
| Abbvie | Meals · 2025-11-13 | Botox | $149 |
| Abbvie | Meals · 2025-10-03 | Botox | $112 |
| Jazz Pharmaceuticals | Consulting · 2025-09-12 | None | $400 |
| Jazz Pharmaceuticals | Consulting · 2025-09-12 | None | $400 |
| Jazz Pharmaceuticals | Consulting · 2025-09-12 | None | $400 |
| Abbvie | Meals · 2025-07-31 | Botox | $150 |
| Jazz Pharmaceuticals | Consulting · 2025-07-11 | None | $800 |
| Jazz Pharmaceuticals | Consulting · 2025-07-11 | None | $400 |
| Jazz Pharmaceuticals | Consulting · 2025-07-11 | None | $400 |
| Jazz Pharmaceuticals | Consulting · 2025-07-11 | None | $200 |
| Jazz Pharmaceuticals | Consulting · 2025-07-11 | None | $200 |
| Jazz Pharmaceuticals | Consulting · 2025-04-22 | None | $2,000 |
| Jazz Pharmaceuticals | Consulting · 2025-04-22 | None | $1,600 |
| Jazz Pharmaceuticals | Consulting · 2025-04-22 | None | $1,400 |
See earlier years (2024, 2023, 2020, 2019)
2024: $21,600
| Jazz Pharmaceuticals | None | $21,600 | 4 payments
|
2023: $23,304
| Jazz Pharmaceuticals | Jzp-441 | $23,200 | 4 payments
|
| Vanda Pharmaceuticals | None | $104 | 1 payment
|
2020: $76
| Vanda Pharmaceuticals | None | $76 | 1 payment
|
2019: $49
| Vanda Pharmaceuticals | None | $49 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Vanda Pharmaceuticals Inc. · 2023 | This clinician | $52,000 |
| Vanda Pharmaceuticals Inc. · 2020 | This clinician | $48,000 |
| Vanda Pharmaceuticals Inc. · 2019 | This clinician | $48,000 |
| Vanda Pharmaceuticals Inc. · 2021 | This clinician | $48,000 |
| Vanda Pharmaceuticals Inc. · 2022 | This clinician | $44,000 |
| Vanda Pharmaceuticals Inc. · 2024 | This clinician | $14,000 |
| Vanda Pharmaceuticals Inc. · 2025 | This clinician | $1,250 |
Professional record
- NPI
- 1811123441
- Licence
- PA MD445137
- Trained
- University of California, San Francisco School of Medicine, 2008
- Group
- UCSF Medical Group Business Services · University of California San Francisco
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2009-06-10
- NPI last updated
- 2020-05-29
- NPI record certified
- 2020-05-29
This is when the NPI record was last certified, not a medical board exam.